Emily Murphy
Family · Neosho, MONPI 1982206066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,480, 2.3 times the $643 reported in 2022. Among family clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$655
- AbbVie$502
- Novo Nordisk$370
- Lilly USA, LLC$312
- Otsuka America Pharmaceutical, Inc.$168
- GSK$148
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,771100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $655 |
| AbbVie | 32 | $502 |
| Novo Nordisk | 22 | $370 |
| Lilly USA, LLC | 19 | $312 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| GSK | 8 | $148 |
| Boehringer Ingelheim | 8 | $146 |
| Pfizer | 7 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $123 |
| Dexcom, Inc. | 7 | $117 |
| Lundbeck LLC | 6 | $116 |
| Ardelyx, Inc. | 3 | $74 |
| Amgen | 4 | $73 |
| Exact Sciences | 4 | $68 |
| Merck | 4 | $64 |
| Astellas Pharma US Inc | 2 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Bayer | 3 | $57 |
| Neurelis, Inc. | 2 | $52 |
| Novartis | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Axsome Therapeutics, Inc. | 3 | $46 |
| Johnson & Johnson | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Tempus AI, Inc | 1 | $26 |
| Shield Therapeutics Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Kerecis Limited | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,771 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $42,234 |
| TrulicityDulaglutide | 31 | $38,585 |
| RexultiBrexpiprazole | 15 | $24,187 |
| FarxigaDapagliflozin Propanediol | 18 | $18,326 |
| InvokanaCanagliflozin | 12 | $7,481 |
| TradjentaLinagliptin | 13 | $7,114 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,507 |
| Gabapentin | 114 | $1,862 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,459 |
| Omeprazole | 85 | $948 |
| Tramadol Hcl | 120 | $647 |
| Montelukast Sodium | 89 | $613 |
| Atorvastatin Calcium | 115 | $609 |
| Duloxetine Hcl | 48 | $570 |
| Fluticasone Propionate | 44 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $370 | $42,23433 claims |
| Lilly USA, LLCTrulicity | $312 | $38,58531 claims |
| AstraZenecaFarxiga, Symbicort | $655 | $24,83233 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $168 | $24,18715 claims |
| Johnson & JohnsonInvokana | $42 | $7,48112 claims |
| Boehringer IngelheimTradjenta | $146 | $7,11413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Neosho
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.